Assessment of postoperative recovery should be multidimensional including physiological parameters, functional recovery parameters, and patient-reported outcomes. Quality of postoperative recovery will be assessed by asking the patient "how have you been feeling during the past 24 hours." Using the Quality of recovery form (QoR15) to document their replies. Quality of recovery (QoR15) score of (0 to 10), where: (0) none of the time (poor) and (10) equal all of the time (excellent). There are a total of 15 questions with each score ranging from 0 to 10. The range of reported total score is 0-150 where higher scores mean better quality of recovery.
Evaluation of Spine Surgery Analgesic Pathway
Brief Summary
Intervention / Treatment
-
Spine surgery analgesic pathway (OTHER)Enhanced pain management care
-
Usual Care (OTHER)Standard of pain management care
Condition or Disease
- Posterior Spine Surgery
Phase
Study Design
Study type: | INTERVENTIONAL |
---|---|
Status: | Completed |
Study results: | No Results Available |
Age: | 18 Years to 80 Years |
Enrollment: | 299 (ACTUAL) |
Funded by: | Other |
Allocation: | Randomized |
Primary Purpose: | Treatment |
MaskingSINGLE:
|
Clinical Trial Dates
Start date: | Jul 01, 2016 | |
---|---|---|
Primary Completion: | Jan 01, 2019 | ACTUAL |
Completion Date: | Jul 16, 2019 | ACTUAL |
Study First Posted: | Sep 02, 2016 | ESTIMATED |
Results First Posted: | Jun 01, 2020 | ACTUAL |
Last Updated: | Dec 15, 2020 |
Sponsors / Collaborators
Location
1. "Usual care" group A
2. "Care pathway" group B
If the participant is randomized to the "spine surgery analgesic pathway" group the participant will be evaluated by the Acute Pain Management Service (APMS) before the surgery for their specific pain management needs. The participant will also get some additional medication for pain in preoperative and intraoperative period. Before surgery the participant will receive Acetaminophen and Gabapentin pills. During the surgery, once the participant is asleep the participant will receive an infusion of ketamine and lidocaine through the participant venous line. After the surgery the participant will receive pain medications as per current standard protocol including acetaminophen and gabapentin. Pain management team specialist will follow for pain control after a surgery as needed.
If the participant is randomized to the "usual care" group the participant will be given placebo preoperatively; the rest of the time pain medication will be provided in a routine manner as per the anesthesia care team and the surgical team. Pain management team specialist will follow for pain control after a surgery as needed.
The primary outcome will be assessed on post-operative day 3: The participants will complete a short survey about quality of recovery.
Participant Groups
-
Before surgery the subject will be given one time oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg). During surgery the subject will receive an infusion of ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start before the incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake). After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed.
-
Placebo- Before surgery the subject will be given one time placebo oral dose Acetaminophen (1000 mg ) and gabapentin (600 mg). Placebo- During surgery the subject will receive a placebo infusion of - ketamine (5 mcg/kg/min) and lidocaine (1.5 mg/kg/hr start at incision and decreased to 1 mg/kg/hr at start of closing and continued to PACU and stop at the first oral intake). After surgery, the surgical team will manage pain medication and will consult acute pain management team as needed.
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 18 |
Maximum Age: | 80 |
Age Groups: | Adult / Older Adult |
Healthy Volunteers: | Yes |
* 18 to 80 years old at time of surgery - Adult patients differ from pediatric patients in that adult spines are stiffer than pediatric patients.
* Posterior spine surgery
* Surgery performed at Cleveland Clinic main campus
Exclusion Criteria:
* Allergy or hypersensitivity to lidocaine, ketamine, acetaminophen, gabapentin
* Current or recent drug abuse (within past 6 months)
* Pregnancy
* Immune system disease such as HIV, AIDS
* Undergoing immunosuppressive treatment
* Recent history of sepsis
* Contraindications to lidocaine such as heart block and hepatic insufficiency
* Heart failure with ejection fraction less than 30%
* Liver dysfunction manifested with increased liver enzymes to double the normal and INR of 2 or higher
Primary Outcomes
Secondary Outcomes
-
Opioid consumption within the initial 48 h was converted to IV morphine equivalents using the conversions specified in Supplemental Digital Content 1 (http:// links.lww.com/ALN/C178).
-
Postoperative pain was evaluated with numeric rating scores (0-10) at 15-min intervals for the initial two postoperative hours or until discharge, whichever came first. A time-weighted averages pain score is equal to the sum of the portion of each time interval (as a decimal, such as 0.25h) multiplied by the levels of the pain (0-10 numeric rating scores) during the time period divided by 48h.
-
Opioid-Related Symptom Distress Scale (ORSDS) evaluates opioid-related side effects. ORSDS is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 opioid-related side effects. The mean of the 12 scores are reported with a range from 0-4 where the higher scores mean more opioid-related side effects.
-
Opioid-Related Symptom Distress Scale (ORSDS) evaluates opioid-related side effects. ORSDS is a 4-point scale that evaluates 3 symptom distress dimensions (frequency, severity, bothersomeness) for 12 opioid-related side effects. The mean of the 12 scores are reported with a range from 0-4 where the higher scores mean more opioid-related side effects.
Other Outcomes
-
The patient satisfaction with pain management at discharge using (NRS 1-100) or on POD 3 or discharge, whichever comes earlier. The higher score means a better outcome
-
Quality of postoperative recovery will be assessed by asking the patient "how have you been feeling during the past 24 hours." Using the Quality of recovery form (QoR15) to document their replies. Quality of recovery (QoR15) score of (0 to 10), where: (0) none of the time (poor) and (10) equal all of the time (excellent). There are a total of 15 questions with each score ranging from 0 to 10. The range of reported total score is 0-150 where higher scores mean better quality of recovery.
-
Using EQ-5D questionnaire for pain disability measurements, at 3 months with the flexibility of +/- 5 days using the EQ-5D questionnaire (0) no pain to (10) worst pain. EQ-5D is a standardized measure of health status developed by EuroQol GROUP
-
It is one of several instruments used to verify the quality-adjusted life years associated with a health state. It is defined as a survey instrument for measuring economic preferences for health states based on the assessment of mobility, self-care, usual activities, pain/discomfort and anxiety/depression (5 items in total). Each dimension has 3 levels: 1=no problem, 2=moderate problem, 3=severe problem. The total scores are calculated for each subject.
-
The exploratory outcome chronic postsurgical pain at 3 months was assessed by phone call using a numeric rating scale (0 to 10) where a score of 0 is "no pain" and a score of 10 is "pain as bad as it could be."
-
Postoperative-anesthesia care unit (PACU) length of stay measured how many hours the patient had spent in PACU.
-
Postoperative nausea and vomiting was assessed using Postoperative Nursing Progress Record (NPR) - Records nausea vomiting severity as 0=none, 1= mild, 2=moderate, 3= severe.
-
Postoperative length of hospital stay measured how many days the patient had spent in the hospital after surgery.
-
The outcome measured how many patients needed acute pain consultation after the surgery, as determined by clinical need
More Details
NCT Number: | NCT02887404 |
---|---|
Other IDs: | 16-012 |
Study URL: | https://clinicaltrials.gov/study/NCT02887404 |